Zentalis Pharmaceuticals, Inc. (ZNTL) Institutional Ownership

Ownership Summary

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has 84 institutional investors that have filed 13F reports for the period ending December 2025.

• Collectively, these holders controlled 56.3% of Zentalis Pharmaceuticals's outstanding shares in December 2025, down from 76.2% in September 2025.
• They increased total shares held in Zentalis Pharmaceuticals by 10.64% from last quarter, and the number of investors in ZNTL decreased 40.0% annually.
• Of these 84 funds, 37 grew their exposure to Zentalis Pharmaceuticals, 32 cut back, and 15 maintained positions.
• Altogether, these fund groups held 40.6Mn shares in ZNTL by December 2025, up by 3.91Mn shares quarter on quarter, and down 25.73Mn shares year over year.
• 5AM Venture Management, LLC leads ownership in ZNTL with 3.95Mn shares as of December 31, 2025, equal to 5.47% of outstanding shares.
• The largest buyers of Zentalis Pharmaceuticals for the quarter ending December 2025 were Squadron Capital Management LLC (3.63Mn), VANGUARD CAPITAL MANAGEMENT LLC (2.31Mn), TWO SIGMA INVESTMENTS, LP (1.49Mn), Qube Research & Technologies Ltd (619.64K), MILLENNIUM MANAGEMENT LLC (616.69K).
• The biggest sellers of Zentalis Pharmaceuticals for the quarter ending December 2025 included Opaleye Management Inc. (1.39Mn), RENAISSANCE TECHNOLOGIES LLC (945.6K), GSA CAPITAL PARTNERS LLP (549.17K), UBS Group AG (518.89K), Morgan Stanley (453.45K).
• Per Business Quant data, the top 10 holders of Zentalis Pharmaceuticals for the quarter ending December 2025 are 5AM Venture Management, LLC (3.95Mn), Squadron Capital Management LLC (3.63Mn), TWO SIGMA INVESTMENTS, LP (2.96Mn), ACADIAN ASSET MANAGEMENT LLC (2.85Mn), VANGUARD CAPITAL MANAGEMENT LLC (2.31Mn), RENAISSANCE TECHNOLOGIES LLC (1.94Mn), CITADEL ADVISORS LLC (1.73Mn), D. E. Shaw & Co., Inc. (1.48Mn), Opaleye Management Inc. (1.41Mn), Decheng Capital LLC (1.32Mn).